Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
A clinical study to investigate the safety of multiple doses of DEN-181 in rheumatoid arthritis patients
Scientific title
A Phase I, randomised, double-blind, placebo-controlled, single centre, multiple-dose ranging study to investigate the safety, tolerability, and pharmacodynamics of subcutaneously administered DEN-181 in adult patients with ACPA+ rheumatoid arthritis on stable treatment with methotrexate.

Secondary ID [1] 293008 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 304921 0
Condition category
Condition code
Inflammatory and Immune System 304251 304251 0 0
Rheumatoid arthritis

Study type
Description of intervention(s) / exposure
Randomised double blind, placebo-controlled, single centre,study of three administrations of DEN-181 at two dose levels (15 active, 5 placebo per dose level).
DEN-181 is a liposomal formulation encapsulating two active pharmaceutical ingredients, calcitriol (0.6 ug/mL) and collagen II peptide (42 ug/mL; 15 amino acid peptide corresponding to collagen II protein 259-273 (Proline 273 Hydroxyproline substitution).
Dose levels will be selected from 100µL, 300uL, or 1000µL DEN-181 and chosen following the single dose arm of this study. DEN-181 will be delivered by subcutaneous injection at weekly intervals for three weeks.
Intervention code [1] 299249 0
Treatment: Drugs
Comparator / control treatment
The study is placebo controlled. The placebo is normal saline (0.9% Sodium Chloride).
Control group

Primary outcome [1] 303536 0
Clinical safety observations including changes in:
Vital signs, Symptom directed physical examination, Adverse events (graded according to Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03), Laboratory abnormalities (Haematology including ESR and Clinical chemistry including CRP in serum samples), Urinalysis
Timepoint [1] 303536 0
For the 56 day study period.
Assessment of primary outcomes will be conducted Day 1, 8 , 15 and 29 and at day 57 (exit evaluation).
Secondary outcome [1] 339220 0
Proportion and total number of naïve, effector and regulatory T-cells by flow cytometry (composite outcome).

Timepoint [1] 339220 0
Assessment of the proportion and total number of naïve, effector and regulatory T-cells will be conducted on study day 1, 8, and 29.

Secondary outcome [2] 339518 0
Determination of the concentration of calcitriol in plasma samples.
Timepoint [2] 339518 0
Assessment of plasma calcitrol concentration will be conducted on day 1, 8 and 15.
Secondary outcome [3] 339519 0
Mean changes in DAS28CRPv4 (Disease Activity Score 28 including CRP assessment 4 variable calculation) scoring system.
Timepoint [3] 339519 0
Assessment of changes in DAS28CRPv4 scoring system will be conducted on day 1, 8, 15, 29, 57.
Secondary outcome [4] 339839 0
Phenotype of naïve, effector and regulatory T-cells by flow cytometry.
Timepoint [4] 339839 0
Assessment of the phenotype of naïve, effector and regulatory T-cells will be conducted on study day 1, 8, and 29.

Key inclusion criteria
Diagnosis of RA made by a rheumatologist;
HLA-DRB1*0401+, HLA-DRB1*0101+ or HLA-DRB1*0401+HLADRB1*0101+ heterozygotes, homozygotes or compound heterozygotes and ACPA+;
Treatment with MTX at the same dose for at least 4 weeks prior to planned start of trial treatment;
Age 18-75 years, inclusive;
Male or female. Females of child-bearing potential must agree to use two effective forms of contraception from enrolment to completion of the study;
Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines;
Blood glucose, CBC, haemoglobin, platelets, creatinine, bilirubin, and AST/ALT not greater than 1.5 x out of normal laboratory ranges at entry and clinically insignificant in opinion of investigator;
Patients agree to forego vaccinations during the course of the study.
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
An active inflammatory disease other than RA;
Currently receiving or have received treatment with >10mg prednisone daily within the last 2 weeks prior to screening;
Current or recent treatment (< 2 weeks prior) with any diseasemodifying anti-rheumatic drugs (DMARDS) other than MTX;
Serious infection requiring hospitalisation within last 28 days;
Receipt of any live attenuated vaccines within 4 weeks prior to entry;
Major surgery within last 28 days;
Significant cardiovascular, renal, liver, neurological or skin disease;
Positive serology for HIV, or infection with HBV or HCV;
Current treatment with cytotoxic or immunomodulatory therapies such as radiotherapy, cyclophosphamide, mycophenolate, tacrolimus, PUVA, acitretin cyclosporine or azathioprine;
Any known or suspected allergies to the study drug or its constituents including egg products;
Inadequate venous access to allow collection of blood samples;
History of drug or alcohol abuse;
Participation in any other clinical trial;
If, in the opinion of the PI, the subject appears not to be able to perform the needed responsibilities of participation in the clinical study.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The pharmacist or responsible party will prepare the treatment corresponding to the subject number in the randomisation plan.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A randomisation scheme will be prepared in advance by the study statistician using a computer generated system according to relevant SOPs.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis
No formal sample size calculations were performed for this study.

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 9129 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 17636 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 297636 0
Commercial sector/Industry
Name [1] 297636 0
Dendright Pty Ltd
Address [1] 297636 0
Translational Research Institute
37 Kent St
Woolloongabba, Qld, 4102
Country [1] 297636 0
Funding source category [2] 297666 0
Name [2] 297666 0
Arthritis Queensland
Address [2] 297666 0
1 Cartwright Street (Cnr Lutwyche Road)
Country [2] 297666 0
Primary sponsor type
Commercial sector/Industry
Dendright Pty Ltd
Translational Research Institute
37 Kent St
Woolloongabba, Qld, 4102
Secondary sponsor category [1] 296655 0
Name [1] 296655 0
Address [1] 296655 0
Country [1] 296655 0

Ethics approval
Ethics application status
Ethics committee name [1] 298723 0
Metro South Health Human Research Ethics Committee
Ethics committee address [1] 298723 0
PAH Centres for Health Research
Level 7, Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Ethics committee country [1] 298723 0
Date submitted for ethics approval [1] 298723 0
Approval date [1] 298723 0
Ethics approval number [1] 298723 0

Brief summary
Current treatments to control damaging immune responses during autoimmunity use broad immunosuppressive drugs associated with undesirable side effects. Alternative strategies to control damaging immune responses are desirable. DEN-181 offers a novel liposomal therapy that does not broadly suppress the immune system, with the associated increased risk of infectious complications, but rather is designed to specifically address the underlying pathology of Rheumatoid arthritis by re-programming the immune system towards tolerance for improved patient outcomes and minimal side effects. This trial will examine the safety, tolerability and preliminary efficacy of DEN-181 in Rheumatoid arthritis patients.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 78018 0
Dr Phillip Vecchio
Address 78018 0
Department Head of Rheumatology
Princess Alexandra Hospital
Ipswich Road
Woolloongabba, 4102 AUSTRALIA
Country 78018 0
Phone 78018 0
+61 7 3391 7500
Fax 78018 0
+61 7 3176 7131
Email 78018 0
Contact person for public queries
Name 78019 0
Ms Joanna Tesiram
Address 78019 0
Clinical Nurse - Biologics/Clinical Trials Coordinator/Clinical Research Nurse Rheumatology Unit |
Division of Medicine
Princess Alexandra Hospital
Metro South Health
199 Ipswich Road
Woolloongabba QLD 4102
Country 78019 0
Phone 78019 0
+61 7 3176 2163
Fax 78019 0
+61 7 3240 7131
Email 78019 0
Contact person for scientific queries
Name 78020 0
Ms Helen Roberts
Address 78020 0
Dendright Pty Ltd
6NE.6006 Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Country 78020 0
Phone 78020 0
+61 (0) 419 657 504
Fax 78020 0
Email 78020 0

No information has been provided regarding IPD availability
Summary results
No Results